Pre-Conference Programming

Pre-Conference Programming

Please note that all Pre-Conferences are taking place at the Marriott Marquis.
WEDNESDAY, MARCH 18, 2020 | 8:00 AM – 5:00 PM. *Sold out - Wait-list only

Sandra Visser, PhD


Sriram Krishnaswami, PhD


INF Pre-Con D Austin

Darren Austin, PhD


Why You Should Attend!

Welcome and step aboard the Model-informed Drug Discovery and Development (MID3) Rollercoaster Workshop where you will experience the highs and lows of (hyper) accelerated drug development. Ten teams of ten participants each will take a small molecule from first in human through to Phase 3 (maybe) with real-time trial execution! This unique workshop will offer attendees an opportunity to submerse themselves in developing a drug and decision-making around this. Participants will gain learnings with respect to decision-making around trial design, dose and schedule selection, therapeutic benefit vision relative to standard of care, changing competitive landscape, and go/no go decisions.

  • The format would be new, interactive, various scenarios, dynamic with real time simulations 
  • At each decision point, some key concepts around interpretation, extrapolation, and decision-making tools will be laid out and discussed in addition to each team rationalizing their decisions.
  • Clinical pharmacology understanding is critical to the determination of the optimal dose. 
  • Emerging external data from competitors and backup compounds will be added to the mix. 
  • Semi-competitive element by keeping a score on decisions that have impact on costs and time.
High Level Summary of Workshop
  • Teams will start with the following 
  • Simulated Phase 1 results for PK + Biomarker for single and repeated dose will be distributed 
  • Distribute Phase 2a (POC) results for PK + Biomarker + clinical endpoint + safety info
  • Distribute Phase 2b (dose ranging) results for PK + Biomarker + clinical endpoint + safety info
  • Distribute Phase 3 results for Efficacy and Safety
  • Michael A. Tortorici, PharmD, PhD
  • Jing Liu, PhD
  • Stacey Tannenbaum, PhD
  • Chunze Li, PhD
  • Karthick Vishwanathan, PhD
  • Georgios Vlasakakis, PhD
  • Benjamin Weber, PhD
  • Neeraj Gupta, PhD
  • Ana Hazra, PhD
  • Sreeraj Macha, PhD
  • Tjerk Bueters, PhD
  • Timothy M. Nicholas, PhD
Attendance for the Pre-Conference is limited to 100 attendees. Registration has filled up! Attendees on the wait list will be notified when a spot becomes available. ASCPT is not responsible for travel costs incurred when moving from the waitlist. ASCPT cannot guarantee housing availability.

WEDNESDAY, MARCH 18, 2020 | 8:00 AM – 5:00 PM

Co-sponsored by International Society of Anti-Infective Pharmacology (ISAP) and Society of Infectious Diseases Pharmacists (SIDP)


Matthew Rizk, PhD


Melanie Nicol, PharmD, PhD

University of Minnesota

Why You should Attend!
This Pre-Conference will focus on the role of translational approaches in anti-infective development and clinical pharmacology considerations. The aim is to bring together individuals interested in anti-infective translational approaches, QSP models, and clinical characterization of special populations.  

This Pre-Conference will feature a poster session! 
Tentative Agenda:
  • 8:00 AM— 8:30 AM – Opening remarks and introductions
  • 8:30 AM — 9:15AM – The pivotal role of translation in anti-infective development – Lena E. Friberg, PhD
  • 9:15 AM — 9:40 AM – Current practices in the design and interpretation of in vitro and animal models for anti-infective PK/PD – William Hope, PhD; Mackenzie L. Cottrell, PharmD
  • 9:40 AM —10:05 AM – Novel approaches in mechanistic and QSP models in anti-infective development – Gauri G. Rao, PharmD
  • 10:05 AM — 10:20 AM – Break
  • 10:20 AM — 10:45 AM –Assessing combination drug products – Klaus Romero, MD
  • 10:45 AM — 11:30 AM – Panel discussion on translational approaches and the growing role of systems models
  • 11:30 AM — 12:00 PM – Trainee and/or early career presentations 
  • 12:00 PM — 1:00 PM – Networking lunch and Poster Session
  • 1:00 PM — 1:45 PM – Special populations and novel clinical methodologies for anti-infectives – Amit Pai, PharmD
  • 1:45 PM — 2:10 PM – Use of innovative trial designs in anti-infective development – Cavan S. Reilly, PhD
  • 2:10 PM — 2:35 PM – Regulatory considerations and streamlined pathways for anti-infectives – Seong H. Jang, PhD
  • 2:35 PM — 2:50 PM – Break
  • 2:50 PM — 3:15 PM – Understanding patient characteristics and impact on PK/PD – Cornelia Landersdorfer
  • 3:15 PM — 3:40 PM – The role of therapeutic drug monitoring and personalized dosing in anti-infectives – Sebastian Wicha, PhD
  • 3:40 PM – 4:05 PM – Connecting PK/PD to Clinical Outcome – David R. Andes, MD
  • 4:05 PM — 5:00 PM– Panel discussion on clinical development of anti-infectives and ensuring a robust data package
  • Registration is now open. Hurry to secure your seat!

    Photo Gallery
    Recent News
    Contact Us